Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Orelabrutinib Combined With BR/G Followed by Orelabrutinib Maintenance Therapy for Newly Diagnosed Marginal Zone Lymphoma (MZL): A Prospective ,Multicenter, Clinical Study

Next Previous
Trial Profile

Orelabrutinib Combined With BR/G Followed by Orelabrutinib Maintenance Therapy for Newly Diagnosed Marginal Zone Lymphoma (MZL): A Prospective ,Multicenter, Clinical Study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bendamustine (Primary) ; Obinutuzumab (Primary) ; Orelabrutinib (Primary) ; Rituximab (Primary)
  • Indications Marginal zone B-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms Optimize Study

Most Recent Events

  • 27 Feb 2026 Primary end-points are updated to remove safety primary end-point, as well as " 2-year progression-free survival (PFS) rate", retaining only "complete response rate (CRR)" for cohort A and B as the primary end-point.
  • 27 Feb 2026 Planned number of patients changed from 73 to 69.
  • 23 Jul 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top